steven-bln
: Cell Therapeutics mit Übernahmestategien?
Cell Therapeutics (WKN: A0Q8RP ; ISIN: US1509345039) scheint in Übernahmegesprächen mit Repros Therapeutics, Inc. (WKN: 899826 ; ISIN: US98975L1089 ; NASDAQ: RPRX) zu stehen. Der Kurs beider Firmen, vor allem der von CTIC hat deutlich zugelegt:
"Recent reports suggest that not only is Big Pharma active in acquisitions, but also larger biotech firms are showing willingness to utilize their large resource pools to acquire smaller firms in a race to diversify and to build their reach. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Repros Therapeutics, Inc. (NASDAQ: RPRX). Access to the full company reports can be found at:
steven-bln
: Kauf von Rechten eines Krebsmedikamentes
Cell Therapeutics (NASDAQ: CTIC) hat auch angekündigt, die Rechte an einem Krebsmedikament von Chorma Therapeutics zu kaufen.
Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped more than 10% to trade at $0.32 today, shortly after the company announced that it has bought exclusive rights to an anti-cancer drug from Chorma Therapeutics Ltd. Cell Therapeutics said that the rights pertain to marketing and co-development of Chroma?s tosedostat. The company further stated that this drug ?has demonstrated significant anti-tumor responses in blood related cancers and solid tumors in ? trials.?